Search

Your search keyword '"VISCERAL leishmaniasis"' showing total 1,612 results

Search Constraints

Start Over You searched for: Descriptor "VISCERAL leishmaniasis" Remove constraint Descriptor: "VISCERAL leishmaniasis" Publisher public library of science Remove constraint Publisher: public library of science
1,612 results on '"VISCERAL leishmaniasis"'

Search Results

51. Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.

52. Variants of NOD2 in Leishmania guyanensis-infected patients with cutaneous leishmaniasis and correlations with plasma circulating pro-inflammatory cytokines.

53. PCR for detection of Leishmania donovani from microscopically negative tissue smears of suspected patients in Gondar, Ethiopia.

54. Prevalence of post kala-azar dermal leishmaniasis (PKDL) and treatment seeking behavior of PKDL patients in Nepal.

55. Patterns and drivers of Human Visceral Leishmaniasis in Pernambuco (Brazil) from 2007 to 2018.

56. miR-148a regulation interferes in inflammatory cytokine and parasitic load in canine leishmaniasis.

57. Revisiting the diagnosis and treatment of Para Kala-azar Dermal Leishmaniasis in the endemic foci of Bangladesh.

58. Malnutrition-related parasite dissemination from the skin in visceral leishmaniasis is driven by PGE2-mediated amplification of CCR7-related trafficking of infected inflammatory monocytes.

59. Cytokine and phenotypic cell profiles in human cutaneous leishmaniasis caused by Leishmania donovani.

60. Detecting Leishmania in dogs: A hierarchical-modeling approach to investigate the performance of parasitological and qPCR-based diagnostic procedures.

61. Rewriting the history of leishmaniasis in Sri Lanka: An untold story since 1904.

62. Livestock and rodents within an endemic focus of Visceral Leishmaniasis are not reservoir hosts for Leishmania donovani.

63. Correction: Acute kidney injury in patients with Visceral Leishmaniasis in Northwest Ethiopia.

64. Review of the neglected tropical diseases programme implementation during 2012–2019 in the WHO-Eastern Mediterranean Region.

65. Prevalence and determinants of asymptomatic Leishmania infection in HIV-infected individuals living within visceral leishmaniasis endemic areas of Bihar, India.

66. The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001–2018.

67. Following successful anti-leishmanial treatment, neutrophil counts, CD10 expression and phagocytic capacity remain reduced in visceral leishmaniasis patients co-infected with HIV.

68. Test combination to detect latent Leishmania infection: A prevalence study in a newly endemic area for L. infantum, northeastern Italy.

69. Stakeholders' views and perspectives on treatments of visceral leishmaniasis and their outcomes in HIV-coinfected patients in East Africa and South-East Asia: A mixed methods study.

70. Comparative analysis of the gut microbiota of sand fly vectors of zoonotic visceral leishmaniasis (ZVL) in Iran; host-environment interplay shapes diversity.

71. Susceptibility status of the wild-caught Phlebotomus argentipes (Diptera: Psychodidae: Phlebotominae), the sand fly vector of visceral leishmaniasis, to different insecticides in Nepal.

72. Impaired in vitro Interferon-γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation.

73. Comparison of serum cytokine levels in symptomatic and asymptomatic HIV-Leishmania coinfected individuals from a Brazilian visceral leishmaniasis endemic area.

74. Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates.

75. Indoor residual spraying for the control of visceral leishmaniasis: A systematic review.

76. Can floral nectars reduce transmission of Leishmania?

78. miRNA-21 regulates CD69 and IL-10 expression in canine leishmaniasis.

79. Experimental evolution links post-transcriptional regulation to Leishmania fitness gain.

80. Bayesian latent class models for identifying canine visceral leishmaniosis using diagnostic tests in the absence of a gold standard.

81. Efficacy and community-effectiveness of insecticide treated nets for the control of visceral leishmaniasis: A systematic review.

82. Neutrophil-dendritic cell interaction plays an important role in live attenuated Leishmania vaccine induced immunity.

83. Systematic identification of genes encoding cell surface and secreted proteins that are essential for in vitro growth and infection in Leishmania donovani.

84. Axenic interspecies and intraclonal hybrid formation in Leishmania: Successful crossings between visceral and cutaneous strains.

85. Evaluation of urine sample for diagnosis of visceral leishmaniasis using rK-39 immunochromatographic test in Northwest Ethiopia.

86. Species identification and phylogenetic analysis of Leishmania isolated from patients, vectors and hares in the Xinjiang Autonomous Region, The People's Republic of China.

87. Canine leishmaniosis in Tunisia: Growing prevalence, larger zones of infection.

88. Molecular identification of two newly identified human pathogens causing leishmaniasis using PCR-based methods on the 3′ untranslated region of the heat shock protein 70 (type I) gene.

89. Increased levels of cortisol are associated with the severity of experimental visceral leishmaniasis in a Leishmania (L.) infantum-hamster model.

90. IgG3 and IL10 are effective biomarkers for monitoring therapeutic effectiveness in Post Kala-Azar Dermal Leishmaniasis.

91. Estimating human leishmaniasis burden in Spain using the capture-recapture method, 2016–2017.

92. Passive case detection for canine visceral leishmaniasis control in urban Brazil: Determinants of population uptake.

93. Leishmania infantum xenodiagnosis from vertically infected dogs reveals significant skin tropism.

94. Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.

95. Leishmania tarentolae and Leishmania infantum in humans, dogs and cats in the Pelagie archipelago, southern Italy.

96. Interplay of Trypanosome Lytic Factor and innate immune cells in the resolution of cutaneous Leishmania infection.

97. Human leishmaniasis vaccines: Use cases, target population and potential global demand.

98. The increased presence of repetitive motifs in the KDDR-plus recombinant protein, a kinesin-derived antigen from Leishmania infantum, improves the diagnostic performance of serological tests for human and canine visceral leishmaniasis.

99. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.

100. Impact of the dog population and household environment for the maintenance of natural foci of Leishmania infantum transmission to human and animal hosts in endemic areas for visceral leishmaniasis in Sao Paulo state, Brazil.

Catalog

Books, media, physical & digital resources